---
title: "Roth MKM Reaffirms Their Buy Rating on Lifezone Metals (LZM)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285159495.md"
description: "Roth MKM analyst Mike Niehuser has reaffirmed a Buy rating on Lifezone Metals (LZM) with a price target of $8.00. Niehuser, a 5-star analyst with a 49.3% average return and 62.02% success rate, covers the Basic Materials sector. Lifezone Metals holds a Moderate Buy consensus among analysts, with a price target consensus of $7.50."
datetime: "2026-05-05T05:57:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285159495.md)
  - [en](https://longbridge.com/en/news/285159495.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285159495.md)
---

# Roth MKM Reaffirms Their Buy Rating on Lifezone Metals (LZM)

In a report released today, Mike Niehuser from Roth MKM maintained a Buy rating on Lifezone Metals, with a price target of $8.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Niehuser is a 5-star analyst with an average return of 49.3% and a 62.02% success rate. Niehuser covers the Basic Materials sector, focusing on stocks such as Tanzanian Royalty Exploration, American Resources, and 1911 Gold.

Lifezone Metals has an analyst consensus of Moderate Buy, with a price target consensus of $7.50.

### Related Stocks

- [LZM.US](https://longbridge.com/en/quote/LZM.US.md)
- [TRX.US](https://longbridge.com/en/quote/TRX.US.md)
- [AREC.US](https://longbridge.com/en/quote/AREC.US.md)
- [LZM+.US](https://longbridge.com/en/quote/LZM+.US.md)

## Related News & Research

- [Lifezone Metals Q1 revenue rises sharply on Simulus growth](https://longbridge.com/en/news/284768786.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)
- [Why This Analyst Thinks Texas Instruments Stock Is on the Path to $1 Trillion](https://longbridge.com/en/news/286957345.md)
- [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md)
- [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)